Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US

Rhea-AI Summary

Sanofi (NASDAQ:SNY) has announced a significant expansion of its Insulins Valyou Savings Program, offering all Americans access to any Sanofi insulin for $35 per month, regardless of their insurance status. The expanded program, effective January 1, 2026, will be available to patients with commercial insurance, Medicare, or no insurance.

The initiative will cover all Sanofi insulins at most pharmacies across the US, including independent and rural locations. Patients can obtain any combination, type, and quantity of Sanofi insulins with a valid prescription at this fixed monthly price. The program aims to eliminate financial barriers that may lead to medication rationing or dose skipping.

Positive

• Program ensures affordable insulin access at $35 per month for all Americans
• Coverage includes all Sanofi insulins regardless of type, combination, or quantity needed
• Wide accessibility through most US pharmacies, including rural and independent locations
• Program available to all patients regardless of insurance status (commercial, Medicare, or uninsured)

Negative

• Program implementation delayed until January 1, 2026

Insights

Healthcare Policy Specialist

Sanofi's $35 insulin cap program broadens access for all Americans, addressing affordability barriers while positioning strategically in the insulin market.

Sanofi's expanded Insulins Valyou Savings Program represents a significant policy shift in pharmaceutical pricing, capping monthly insulin costs at $35 for all Americans regardless of insurance status. This goes beyond the Inflation Reduction Act's Medicare insulin cap by including commercially insured and uninsured patients.

The timing is strategic—coming after federal policy changes and amid increased scrutiny of insulin pricing practices. By implementing this program effective January 2026, Sanofi positions itself favorably with policymakers while addressing medication adherence issues that drive healthcare costs.

This initiative addresses a critical healthcare access barrier. Studies show approximately 25% of insulin-dependent patients ration doses due to cost concerns, leading to preventable hospitalizations and complications. By removing financial barriers, Sanofi potentially improves health outcomes while reducing system-wide costs.

From a competitive standpoint, this move follows similar programs from Eli Lilly and Novo Nordisk, completing industry-wide adoption of affordability initiatives among the three major insulin manufacturers. However, Sanofi's approach appears to have fewer restrictions and broader applicability than some competitors' programs.

While positioned as patient-centric, this strategy also likely helps Sanofi maintain market share as biosimilar competition increases and political pressure on insulin pricing continues. The program demonstrates how pharmaceutical companies are adapting business models in response to policy pressures while addressing legitimate patient needs.

Pharmaceutical Industry Analyst

This expanded affordability program represents a calculated strategic move by Sanofi in the highly competitive insulin market. With all major insulin manufacturers now offering some form of cost-capping program, Sanofi's approach stands out by eliminating eligibility restrictions—making it available to Medicare beneficiaries, commercially insured, and uninsured patients alike.

The $35 monthly cap aligns exactly with the Medicare Part D insulin cost-sharing limit established by the Inflation Reduction Act, effectively extending that benchmark across all patient segments. This standardization simplifies messaging and program administration while addressing political pressure on insulin affordability.

From a business perspective, this program likely serves multiple strategic objectives:

• Protecting market share against biosimilar competition by removing cost as a switching factor
• Improving patient adherence, potentially increasing volume
• Enhancing corporate reputation with stakeholders and policymakers
• Preempting potential broader government price controls

The program's pharmacy-level implementation without complex eligibility hurdles suggests Sanofi has developed an efficient administrative mechanism that minimizes barriers to participation. This frictionless approach maximizes program utilization while simplifying the patient experience.

While the immediate revenue impact could be negative for high-list-price prescriptions, the program may actually improve net revenue by increasing adherence, reducing rebate expenses to certain payers, and potentially growing prescription volume through competitive differentiation. The January 2026 implementation timeline provides ample opportunity for Sanofi to adjust contracting strategies with payers to accommodate this pricing change.

MORRISTOWN, N.J., Sept. 26, 2025 /PRNewswire/ -- Sanofi US today announces a broad expansion of its Insulins Valyou Savings Program by offering a 30-day supply of any Sanofi insulin for $35 to all patients in the US with a valid prescription. The program, first created for people without health insurance, will be available to all Americans regardless of insurance status, including those with commercial insurance or Medicare, to ensure affordable access to these critical medicines.

Sanofi's expanded Insulins Valyou Savings Program now ensures no American needs to pay more than $35 per month for their Sanofi insulins.

"Our announcement builds on an idea first championed by President Trump to lower costs for American patients at the pharmacy counter. At Sanofi, we share his objective and believe that no one should struggle to afford their insulin and we are proud to take this next step as we play our part to keep America healthy," said Adam Gluck, Head of US Corporate Affairs, Sanofi. "By expanding our Insulins Valyou Savings Program, we're taking concrete action to address a critical healthcare issue for millions of Americans living with diabetes. We will continue to work with policymakers and stakeholders across the healthcare system on additional sustainable, long-term solutions to improve access to medicines."

Sanofi's Insulins Valyou Savings Program works at most pharmacies across the US, including independent and rural pharmacies, without creating complex hurdles for patients.

The expanded program will cover all Sanofi insulins and will be implemented nationwide. This initiative builds on Sanofi's longstanding commitment to access and affordability. Under this expansion, every American will be able to purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for a fixed monthly price of $35.

"Diabetes management requires consistent access to medication, and financial barriers can lead to rationing or skipping doses, which can have serious health consequences," said Olivier Bogillot, Head of General Medicines, North America, Sanofi. "This program expansion emphasizes our continued support for America's diabetes community."

The expanded Insulins Valyou Savings Program will be available to patients beginning January 1, 2026. Patients can enroll at Sanofi Patient Connection or by calling 1-888-847-4877.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com

Investor Relations
Thomas Kudsk Larsen |+44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Felix Lauscher | +1 908 612 7239 | felix.lauscher@sanofi.com
Keita Browne | +1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com
Tarik Elgoutni | +1 617 710 3587 | tarik.elgoutni@sanofi.com
Thibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com

Sanofi forward-looking statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

All trademarks mentioned in this press release are the property of the Sanofi group.

View original content:https://www.prnewswire.com/news-releases/sanofi-expands-patient-affordability-program-by-offering-access-to-all-its-insulins-for-35-per-month-in-the-us-302567711.html

SOURCE Sanofi

FAQ

What is Sanofi's new insulin pricing program for 2026?

Starting January 1, 2026, Sanofi will offer all its insulin products to Americans for $35 per month through the expanded Insulins Valyou Savings Program, regardless of insurance status.

How can patients enroll in Sanofi's $35 insulin program?

Patients can enroll in the program through Sanofi Patient Connection or by calling 1-888-847-4877.

Who is eligible for Sanofi's $35 insulin program?

The program is available to all Americans with a valid prescription, including those with commercial insurance, Medicare, or no insurance coverage.

Where can patients access Sanofi's $35 insulin program?

The program works at most pharmacies across the US, including independent and rural pharmacies, without complex hurdles for patients.

What types of insulin are covered under Sanofi's $35 program?

The program covers all Sanofi insulin products, allowing patients to purchase any combination, type, and quantity with a valid prescription.